UnitedHealth Group Inc. - 10-Q Summary (Quarter Ended September 30, 2006)
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2006. The filing is a restatement of previously issued financial information for the periods ended September 30, 2005, and December 31, 2005, as well as the quarter ended March 31, 2006. The restatement was necessitated by an independent review of the Company's historic stock option grant practices (1994–2005), which concluded that incorrect measurement dates were used, requiring additional stock-based compensation expense and related tax adjustments. The Company adopted FAS 123R effective January 1, 2006, using the modified retrospective transition method.
Key Financial Metrics
| Metric | Three Months Ended Sept 30, 2006 | Three Months Ended Sept 30, 2005 (Restated) | Nine Months Ended Sept 30, 2006 | Nine Months Ended Sept 30, 2005 (Restated) |
|---|---|---|---|---|
| Total Revenues | $17,970 million | $11,613 million | $53,414 million | $34,139 million |
| Net Earnings | $1,112 million | $800 million | $2,984 million | $2,305 million |
| Diluted EPS | $0.80 | $0.61 | $2.13 | $1.73 |
| Operating Margin | 10.4% | 11.4% | 9.4% | 11.1% |
| Medical Care Ratio | 81.1% | 79.7% | 81.6% | 80.0% |
| Cash and Cash Equivalents | $9,252 million (Sept 30, 2006) | $5,421 million (Dec 31, 2005) | Balance Sheet Data | |
| Total Debt (Current + Long-Term) | $7,325 million (Sept 30, 2006) | $7,095 million (Dec 31, 2005) | Balance Sheet Data | |
| Operating Cash Flow (9 Months) | N/A | $4,926 million | $3,522 million |
Material Changes vs. Prior Period
- Revenue Growth: Consolidated revenues increased 55% year-over-year for the quarter and 56% for the nine-month period. Excluding acquisitions, organic revenue growth was approximately 20%.
- Profitability: Net earnings increased 39% for the quarter and 29% for the nine-month period. Earnings from operations increased 41% and 32%, respectively.
- Acquisitions: Significant growth is attributed to the December 2005 acquisition of PacifiCare Health Systems, Inc. and the February 2006 acquisition of John Deere Health Care, Inc.
- Medicare Part D: The launch of the Medicare Part D program on January 1, 2006, contributed significantly to premium revenues ($1.4 billion in Q3 and $4.5 billion for the nine months) but also increased the medical care ratio due to the program's benefit design.
- Restatement Impact: The restatement reduced net earnings for the nine months ended September 30, 2005, by $144 million under APB 25 and $35 million under FAS 123R adjustments compared to originally reported figures.
Guidance, Outlook, Risks, and Contingencies
- Stock Option Restatement: The Company concluded that its internal controls over financial reporting had a material weakness as of December 31, 2005, related to stock option plan administration. Management concluded this weakness was reduced to a significant deficiency as of September 30, 2006, and fully remediated as of December 31, 2006.
- Regulatory and Legal Risks: The Company is subject to formal investigations by the SEC, IRS, U.S. Attorney for the Southern District of New York, and the Minnesota Attorney General regarding historic stock option practices. Multiple shareholder derivative and class-action lawsuits are pending.
- Debt Covenants and Litigation: The Company received a notice of default and acceleration regarding $850 million of Senior Unsecured Notes due to delayed filings. The Company filed a declaratory judgment action contesting the default. If unsuccessful, the Company may be required to retire these notes.
- Future Charges: The Company expects to take a charge of approximately $55 million (net of tax) in the first quarter of 2007 related to Section 409A tax costs for certain "discount options" exercised in 2006.
- Stock Repurchases: The Company suspended its stock repurchase program in Q3 2006 pending the completion of the restatement and becoming current in SEC filings. It intends to resume the program in 2007.
Key Facts for Investor Verification
- Restatement Scope: Verify the specific impact of the restatement on historical earnings per share and total equity, noting that all financial statements from 1994 through 2005 and interim periods in 2006 have been restated.
- Legal Proceedings: Monitor the status of the declaratory judgment action regarding the $850 million debt acceleration and the outcomes of the SEC and other regulatory investigations.
- Internal Controls: Confirm the Company's assertion that the material weakness in internal controls was fully remediated by December 31, 2006, and review the effectiveness of new equity award policies.
- Medicare Part D Performance: Assess the medical care ratio for the Medicare Part D program (91% for the nine months ended Sept 30, 2006) and the potential impact of risk-sharing settlements with CMS.
- Upcoming Charges: Account for the anticipated $55 million charge in Q1 2007 related to Section 409A tax liabilities.